Chronic thromboembolic pulmonary vascular disease: physiological concepts and genetic predisposition

Chronic thromboembolic pulmonary hypertension (CTEPH) is an uncommon sequela of acute pulmonary embolism and, untreated, leads to right ventricular (RV) failure and death. Despite its growing recognition, methods for the detection of early RV insufficiency and prediction of clinical deterioration, important to optimum preservation of RV function, are currently suboptimal. Furthermore, underlying genetic predisposition to CTEPH, unexplained by defective fibrinolysis, remains largely unexplored. The RV’s physiological response to chronic thromboembolic obstruction is arguably best described by RV pressure volume loops which, historically, are best obtained using the conductance catheter. Although invasive, conductance has an indisputable advantage over current imaging modalities; catheters measure dynamic ventricular pressure and volume throughout the cardiac cycle. Using this technique, abnormal RV pressure volume loops are demonstrated in response to chronic thrombotic obstruction, independent of resting haemodynamic criteria diagnostic of CTEPH. Pressure volume differences and accrual of an exercise gas exchange deficit further suggest early ‘subclinical’ RV adaptation. The genetic architecture of CTEPH is also explored using high-throughput sequencing of unrelated patients. This shows that rare DNA variants in CTEPH that are predicted to harbour deleterious effects are not over-represented in fibrinolytic pathways. Finally, prognostication in CTEPH is evaluated using a clinical deterioration model which is shown to be predicted by patient-reported outcomes at diagnosis. In conclusion, RV and pulmonary circulatory function in chronic thromboembolic pulmonary vascular disease are inadequately characterised by existing routine methods. Links between the observed physiological deficits, risk of clinical deterioration and abnormal genetic architecture warrant further evaluation in this rare disease.Open Acces

Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study

BACKGROUND AND AIMS: Interventional studies in pulmonary arterial hypertension completed to date have shown to be effective in symptomatic patients with significantly elevated mean pulmonary artery pressure (mPAP) (≥25 mmHg) and pulmonary vascular resistance (PVR) > 3 Wood Unit (WU). However, in health the mPAP does not exceed 20 mmHg and PVR is 2 WU or lower, at rest. The ESC/ERS guidelines have recently been updated to reflect this. There is limited published data on the nature of these newly defined populations (mPAP 21-24 mmHg and PVR >2-≤3 WU) and the role of comorbidity in determining their natural history. With the change in guidelines, there is a need to understand this population and the impact of the ESC/ERS guidelines in greater detail. METHODS: A retrospective nationwide evaluation of the role of pulmonary haemodynamics and comorbidity in predicting survival among patients referred to the UK pulmonary hypertension (PH) centres between 2009 and 2017. In total, 2929 patients were included in the study. Patients were stratified by mPAP ( 2-≤3 WU, and >3 WU), with 968 (33.0%) in the mPAP 2-≤3WU) was lower than among those with normal pressures (mPAP <21 mmHg) and normal PVR (PVR ≤ 2WU) independent of comorbid lung and heart disease [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.14-1.61, P = .0004 for mPAP vs. HR 1.28, 95% CI 1.10-1.49, P = .0012 for PVR]. Among patients with mildly elevated mPAP, a mildly elevated PVR remained an independent predictor of survival when adjusted for comorbid lung and heart disease (HR 1.33, 95% CI 1.01-1.75, P = .042 vs. HR 1.4, 95% CI 1.06-1.86, P = .019). 68.2% of patients with a mPAP 21-24 mmHg had evidence of underlying heart or lung disease. Patients with mildly abnormal haemodynamics were not more symptomatic than patients with normal haemodynamics. Excluding patients with heart and lung disease, connective tissue disease was associated with a poorer survival among those with PH. In this subpopulation evaluating those with a mPAP of 21-24 mmHg, survival curves only diverged after 5 years. CONCLUSIONS: This study supports the change in diagnostic category of the ESC/ERS guidelines in a PH population. The newly included patients have an increased mortality independent of significant lung or heart disease. The majority of patients in this new category have underlying heart or lung disease rather than an isolated pulmonary vasculopathy. Mortality is higher if comorbidity is present. Rigorous phenotyping will be pivotal to determine which patients are at risk of progressive vasculopathic disease and in whom surveillance and recruitment to studies may be of benefit. This study provides an insight into the population defined by the new guidelines

Ventriculo-arterial coupling detects occult RV dysfunction in chronic thromboembolic pulmonary vascular disease.

Chronic thromboembolic disease (CTED) is suboptimally defined by a mean pulmonary artery pressure (mPAP)  0.68 and Ees/Ea < 0.68 subgroups demonstrated constant RV stroke work but lower stroke volume (87.7 ± 22.1 vs. 60.1 ± 16.3 mL respectively, P = 0.006) and higher end-systolic pressure (36.7 ± 11.6 vs. 68.1 ± 16.7 mmHg respectively, P < 0.001). Lower Ees/Ea in CTED also correlated with reduced exercise ventilatory efficiency. Low Ees/Ea aligns with features of RV maladaptation in CTED both at rest and on exercise. Characterization of Ees/Ea in CTED may allow for better identification of occult RV dysfunction

Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH

Abstract: Background: Pulmonary arterial hypertension (PAH) is a lethal vasculopathy characterized by pathogenic remodeling of pulmonary arterioles leading to increased pulmonary pressures, right ventricular hypertrophy, and heart failure. PAH can be associated with other diseases (APAH: connective tissue diseases, congenital heart disease, and others) but often the etiology is idiopathic (IPAH). Mutations in bone morphogenetic protein receptor 2 (BMPR2) are the cause of most heritable cases but the vast majority of other cases are genetically undefined. Methods: To identify new risk genes, we utilized an international consortium of 4241 PAH cases with exome or genome sequencing data from the National Biological Sample and Data Repository for PAH, Columbia University Irving Medical Center, and the UK NIHR BioResource – Rare Diseases Study. The strength of this combined cohort is a doubling of the number of IPAH cases compared to either national cohort alone. We identified protein-coding variants and performed rare variant association analyses in unrelated participants of European ancestry, including 1647 IPAH cases and 18,819 controls. We also analyzed de novo variants in 124 pediatric trios enriched for IPAH and APAH-CHD. Results: Seven genes with rare deleterious variants were associated with IPAH with false discovery rate smaller than 0.1: three known genes (BMPR2, GDF2, and TBX4), two recently identified candidate genes (SOX17, KDR), and two new candidate genes (fibulin 2, FBLN2; platelet-derived growth factor D, PDGFD). The new genes were identified based solely on rare deleterious missense variants, a variant type that could not be adequately assessed in either cohort alone. The candidate genes exhibit expression patterns in lung and heart similar to that of known PAH risk genes, and most variants occur in conserved protein domains. For pediatric PAH, predicted deleterious de novo variants exhibited a significant burden compared to the background mutation rate (2.45×, p = 2.5e−5). At least eight novel pediatric candidate genes carrying de novo variants have plausible roles in lung/heart development. Conclusions: Rare variant analysis of a large international consortium identified two new candidate genes—FBLN2 and PDGFD. The new genes have known functions in vasculogenesis and remodeling. Trio analysis predicted that ~ 15% of pediatric IPAH may be explained by de novo variants

Adolescents in Sports: the All-Delinquent Team

Analyzed through the lens of social-bond theory, this thesis examines the relationship between sports participation and delinquency among adolescents. The purpose of this thesis is to better understand whether sports can serve as an effective intervention strategy for policy makers, government agencies and criminal justice branches that deal directly with at risk-youth or offenders who can benefit from sports-related programs. Through the use of a meta-analysis methodological design, the findings uncovered through common literature will reflect the extent to which social-bond theory can sufficiently explain delinquency among athletes. Traditionally, sports-participation and physical activity have been connected to prosocial stereotypes and the belief that adolescents will develop character-building morals. Although many situations including sports-participation are mainly positive across most facets, there is further evidence to suggest that unintended, antisocial-developing consequences can arise from participation in sports-related activities. Jock identity and unstructured socializing were highlighted as major factors for delinquency among athletes, whereas the pedagogical sports-environment serves as a possible deterrence model for delinquency. With further extensive research into this topic, the development of a pedagogical sports model can provide more athletes with an exceptional prosocial experience. Similarly, sports participation and sports-related intervention strategies can be utilized to address and combat youth-crime

Cardiopulmonary exercise testing differentiates resting pulmonary hypertension in patients with exercise limitation and persistent pulmonary vascular obstruction following acute pulmonary embolism

info:eu-repo/semantics/nonPublishe

Heightened ventilatory response during stair climbing in individuals with dysfunctional breathing

This prospective cohort study confirms that patients with dysfunctional breathing experience dyspnoea and an abnormal breathing pattern when faced with undertaking everyday exercise challenges, such as climbing stairs https://bit.ly/3OEWwP

Direct oral anticoagulants for cancer associated venous thromboembolisms: a systematic review and network meta-analysis : DOACs for VTE in Cancer

Several recent randomized controlled trials (RCTs) have investigated the use of direct oral anticoagulants (DOACs) in the treatment of malignancy associated venous thromboembolisms (VTE).This meta-analysis combines all RCT data to determine the risks of recurrent VTE and bleeding with DOACs in patients with malignancy associated VTE compared to low molecular weight heparin (LMWH).The study followed PRISMA guidelines. MEDLINE, EMBASE, CENTRAL were systematically searched from inception to 1st of April 2020. References of reviews and relevant conference proceedings were hand-searched. Two authors independently evaluated study eligibility, extracted data, and assessed risk-of-bias. Direct and indirect meta-analyses were performed.In four RCTs with low risk-of-bias (2907 patients), high certainty evidence suggested that DOACs had a 37% reduction in risk of recurrent VTE compared to LMWH (direct pooled risk ratio (RR) 0.63, 95%CI 0.44-0.91; I = 28%). No significant difference was observed in the risk of major bleeding with DOACs compared to LMWH (RR 1.31, 95%CI 0.83-2.07; I = 22%; moderate certainty evidence), including in patients in gastrointestinal and genitourinary malignancy. An increased risk of combined major or CRNMB was seen with DOACs (RR 1.52, 95%CI 1.09-2.12; I = 51%; low certainty evidence). Apixaban had the highest probability of being ranked most effective and least bleeding risk amongst the DOACs.DOACs are effective in treating malignancy associated VTE, however caution is required in patients with high risk of bleeding. Apixaban had lower risk of bleeding compared to other DOACs in this population. This article is protected by copyright. All rights reserved